Neurofibromatosis type 1

Active Research Protocols

  1. 01-C-0027 – Natural History of Plexiform in Neurofibromatosis Type I
  2. 04-C-0080 – Phase II Trial of Pirfenidone in Children, Adolescents, and Young Adults with Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
  3. 05-HG-0152 – Variation in Gene Expression in Neurofibromatosis Type 1
  4. 06-C-0043 – Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors
  5. 06-HG-0134 – Natural History and Biology of Dermal Neurofibromas in Neurofibromatosis Type 1
  6. 08-C-0079 – Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1
  7. 08-C-0096 – A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
  8. 08-C-0130 – A Phase II Trial of Peginterferon Alpha-2b (PEG-Intron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas
  9. 09-M-0022 – The Use of a Distress Thermometer in a Pediatric Research Setting: An Exploratory, Pilot Study
  10. 11-C-0161 – A Phase 1 Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor AZD6244 Hydrogen Sulfate (Selumetinib Sulfate) in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
  11. 12-C-0058 – A Phase II Study of Everolimus (RAD001) for Children with Neurofibromatosis Type-1 and Chemotherapy-Refractory Radiographic Progressive Low-Grade Gliomas
  12. 12-C-0148 – SARC016: Phase 2 Study of the mTOR Inhibitor Everolimus in Combination with Bevacizumab in Patients with Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
  13. 12-C-0155 – Acceptance and Commitment Therapy for Adolescents and Adults with Neurofibromatosis Type 1 and Chronic Pain: A Pilot Study
  14. 12-C-0160 – Validation of the English Version of the Pain Interference Index and the Pain Rating Scale in Children, Adolescents, and Young Adults with Chronic Illness and their Parents
NOTE: PDF documents require the free
Adobe Reader.
This page was last updated: January 24, 2014